In ovarian cancer, aberrant C5aR expression on TAMs induces an immunosuppressive phenotype, whereas genetic or pharmacological C5aR blockade reprograms TAMs, restores CXCL9 production, enhances CD8+ T cell infiltration, and improves the efficacy of immune checkpoint inhibition (83). Here, C5AR1 is linked to ovarian cancer.